Vaxcyte Total Current Liabilities vs Common Stock Shares Outstanding Analysis

PCVX Stock  USD 93.98  2.53  2.77%   
Vaxcyte financial indicator trend analysis is much more than just breaking down Vaxcyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxcyte is a good investment. Please check the relationship between Vaxcyte Total Current Liabilities and its Common Stock Shares Outstanding accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Total Current Liabilities vs Common Stock Shares Outstanding

Total Current Liabilities vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxcyte Total Current Liabilities account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Vaxcyte's Total Current Liabilities and Common Stock Shares Outstanding is 0.82. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Vaxcyte, assuming nothing else is changed. The correlation between historical values of Vaxcyte's Total Current Liabilities and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Vaxcyte are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Total Current Liabilities i.e., Vaxcyte's Total Current Liabilities and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.82
Relationship DirectionPositive 
Relationship StrengthStrong

Total Current Liabilities

Total Current Liabilities is an item on Vaxcyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vaxcyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from Vaxcyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxcyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.Selling General Administrative is likely to rise to about 63.7 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 364.6 M in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization1.8M9.2M3.2M4.0M
Net Interest Income337K8.4M62.9M66.1M

Vaxcyte fundamental ratios Correlations

0.920.950.99-0.940.99-0.990.540.730.2-0.730.990.86-0.730.880.521.00.960.870.850.94-0.67-0.760.930.910.76
0.920.990.9-0.790.87-0.940.450.44-0.12-0.60.880.78-0.60.740.580.880.840.760.730.98-0.53-0.480.990.990.58
0.950.990.93-0.850.91-0.960.560.53-0.04-0.680.920.82-0.680.830.560.920.90.790.80.97-0.61-0.560.970.970.68
0.990.90.93-0.961.0-0.980.540.750.23-0.690.990.84-0.690.890.420.990.970.880.860.92-0.64-0.780.910.890.77
-0.94-0.79-0.85-0.96-0.970.93-0.6-0.81-0.440.74-0.96-0.840.74-0.95-0.36-0.96-0.98-0.92-0.92-0.840.70.82-0.81-0.77-0.88
0.990.870.911.0-0.97-0.970.570.80.3-0.741.00.86-0.740.910.441.00.980.890.880.9-0.69-0.820.880.850.81
-0.99-0.94-0.96-0.980.93-0.97-0.51-0.66-0.190.75-0.97-0.890.75-0.88-0.57-0.97-0.96-0.9-0.86-0.970.690.68-0.95-0.93-0.76
0.540.450.560.54-0.60.57-0.510.620.11-0.70.570.63-0.70.740.30.570.660.360.720.37-0.69-0.610.370.360.77
0.730.440.530.75-0.810.8-0.660.620.53-0.670.80.71-0.670.740.30.80.770.610.720.46-0.67-0.990.430.390.76
0.2-0.12-0.040.23-0.440.3-0.190.110.53-0.460.260.31-0.460.45-0.020.260.370.530.370.04-0.5-0.48-0.04-0.120.55
-0.73-0.6-0.68-0.690.74-0.740.75-0.7-0.67-0.46-0.74-0.861.0-0.86-0.63-0.75-0.83-0.74-0.75-0.621.00.65-0.59-0.55-0.84
0.990.880.920.99-0.961.0-0.970.570.80.26-0.740.87-0.740.890.51.00.970.860.850.9-0.69-0.820.880.860.78
0.860.780.820.84-0.840.86-0.890.630.710.31-0.860.87-0.860.860.670.870.890.810.910.79-0.84-0.680.770.740.87
-0.73-0.6-0.68-0.690.74-0.740.75-0.7-0.67-0.461.0-0.74-0.86-0.86-0.63-0.75-0.83-0.74-0.75-0.621.00.65-0.59-0.55-0.84
0.880.740.830.89-0.950.91-0.880.740.740.45-0.860.890.86-0.860.40.890.970.890.930.79-0.84-0.740.750.710.95
0.520.580.560.42-0.360.44-0.570.30.3-0.02-0.630.50.67-0.630.40.50.460.410.410.53-0.6-0.260.540.540.37
1.00.880.920.99-0.961.0-0.970.570.80.26-0.751.00.87-0.750.890.50.970.870.860.9-0.7-0.820.880.860.78
0.960.840.90.97-0.980.98-0.960.660.770.37-0.830.970.89-0.830.970.460.970.910.920.88-0.79-0.780.850.820.89
0.870.760.790.88-0.920.89-0.90.360.610.53-0.740.860.81-0.740.890.410.870.910.830.87-0.71-0.610.820.770.8
0.850.730.80.86-0.920.88-0.860.720.720.37-0.750.850.91-0.750.930.410.860.920.830.77-0.72-0.70.740.710.96
0.940.980.970.92-0.840.9-0.970.370.460.04-0.620.90.79-0.620.790.530.90.880.870.77-0.55-0.491.00.990.63
-0.67-0.53-0.61-0.640.7-0.690.69-0.69-0.67-0.51.0-0.69-0.841.0-0.84-0.6-0.7-0.79-0.71-0.72-0.550.64-0.52-0.47-0.84
-0.76-0.48-0.56-0.780.82-0.820.68-0.61-0.99-0.480.65-0.82-0.680.65-0.74-0.26-0.82-0.78-0.61-0.7-0.490.64-0.46-0.43-0.73
0.930.990.970.91-0.810.88-0.950.370.43-0.04-0.590.880.77-0.590.750.540.880.850.820.741.0-0.52-0.461.00.59
0.910.990.970.89-0.770.85-0.930.360.39-0.12-0.550.860.74-0.550.710.540.860.820.770.710.99-0.47-0.431.00.54
0.760.580.680.77-0.880.81-0.760.770.760.55-0.840.780.87-0.840.950.370.780.890.80.960.63-0.84-0.730.590.54
Click cells to compare fundamentals

Vaxcyte Account Relationship Matchups

Vaxcyte fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets65.7M392.8M324.3M1.0B1.4B1.5B
Other Current Liab7.5M17.1M11.4M18.9M116.5M122.4M
Total Current Liabilities11.1M46.9M28.7M40.5M145.3M152.6M
Total Stockholder Equity(106.4M)345.8M284.0M953.6M1.2B1.3B
Other Liab259K122K96K9K8.1K7.7K
Net Tangible Assets(106.4M)345.8M284.0M953.6M1.1B1.2B
Retained Earnings(109.3M)(198.6M)(298.6M)(522.1M)(924.4M)(878.2M)
Accounts Payable3.4M29.8M6.8M9.8M14.6M10.8M
Cash59.0M386.2M69.0M834.7M397.5M290.5M
Other Assets584K550K5.0M5.4M1.00.95
Cash And Short Term Investments59.0M386.2M246.0M931.4M1.1B1.1B
Common Stock Shares Outstanding48.9M51.1M51.9M64.9M97.2M57.4M
Capital Surpluse1.3M3.0M544.4M582.8M670.3M703.8M
Total Liab172.1M47.0M40.3M52.6M167.4M96.9M
Total Current Assets61.7M389.0M256.3M942.6M1.1B1.2B
Common Stock7K54K56K82K98K102.9K
Property Plant Equipment3.4M3.3M35.9M31.6M36.4M38.2M
Property Plant And Equipment Net3.4M3.3M35.9M31.6M110.6M116.2M
Net Debt(58.8M)(386.2M)(52.2M)(816.7M)(368.2M)(386.6M)
Non Current Assets Total4.0M3.8M68.0M63.6M312.0M327.6M
Non Currrent Assets Other584K550K5.0M5.4M38.7M40.6M
Liabilities And Stockholders Equity65.7M392.8M324.3M1.0B1.4B1.5B
Non Current Liabilities Total161.0M122K11.6M12.0M22.1M43.8M
Capital Lease Obligations161K0.016.8M17.9M29.2M30.7M
Other Current Assets2.7M2.5M9.2M5.3M15.7M16.5M
Other Stockholder Equity3.0M151.5M582.8M1.5B2.2B2.3B
Net Invested Capital(106.4M)345.8M284.0M953.6M1.2B1.3B
Accumulated Other Comprehensive Income(160.3M)(392.8M)(241K)(361K)179K188.0K
Capital Stock7K54K56K82K98K55.6K
Non Current Liabilities Other242K112K96K9K8.1K7.7K
Net Working Capital50.7M342.1M227.6M902.0M950.6M998.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.